VNDA — Vanda Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $413.76m
- $157.39m
- $216.11m
Annual cashflow statement for Vanda Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 33.2 | 6.28 | 2.51 | -18.9 | -220 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 18.7 | 15.8 | 9.31 | 8.05 | 11.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.74 | 6.07 | -0.747 | -6.56 | 8.31 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 64.2 | 32 | 12.8 | -15.8 | -109 |
| Capital Expenditures | -0.552 | -0.679 | -0.383 | -0.49 | -0.998 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -76.1 | 50.6 | -11.7 | -16.9 | 95.9 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -76.7 | 49.9 | -12.1 | -17.4 | 94.9 |
| Financing Cash Flow Items | — | — | — | — | -0.915 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.55 | 0.734 | 0 | -0.155 | -2.91 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -9.02 | 82.9 | 0.792 | -33.5 | -17.5 |